Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 11/20 | 0.36 |
| ▸ | MAOA | P21397 | 9/20 | 0.36 |
| ▸ | MAOB | P27338 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17414380 | 1.00 | ATM (0.38) | ATMKDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL18624657 | 0.84 | NPSR1 (0.36) | ATMKDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL17414375 | 0.78 | ATM (0.38) | ATMKDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL19214521 | 0.70 | TRPA1 (0.41) | KDM1AMAOAMAOBALDH1A1TRPA1 | |
| SCHEMBL17414366 | 0.70 | CHRNB2 (0.38) | ATMKDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL22759043 | 0.68 | KDM1A (0.35) | ATMKDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL18639490 | 0.67 | RORC (0.46) | ATMKDM1AMAOBSIGMAR1 | |
| SCHEMBL22759034 | 0.67 | MAPT (0.35) | KDM1AMAOAMAOBALDH1A1NPSR1 | |
| SCHEMBL22759036 | 0.65 | SIGMAR1 (0.34) | ATMKDM1AMAOAMAOBSIGMAR1 | |
| SCHEMBL23957903 | 0.62 | KDM1A (0.30) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724682-B2 | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170072390-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170072390-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | FTH1, FLI1, FECH | ATM 2965/4885KDM1A 1623/4885MAOA 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.